StreetInsider.com News Articles

Lexaria Bioscience plans three studies for drug delivery research

Wed, 04 Mar 2026 09:25:23 -0500

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced its 2026 research and development program, which includes one human study and two animal studies focused on its DehydraTECH drug delivery platform.

The human study, designated GLP-1-H26-7, will be a five-week parallel group study comparing DehydraTECH-semaglutide tablet and capsule compositions to commercially available Wegovy semaglutide tablets. The study will enroll approximately 75 subjects across three arms, with recruitment expected to begin in April 2026 and final results anticipated in the fourth quarter.

The first animal study, GLP-1-A26-1, will test various formulations including SNAC-inclusive DehydraTECH-semaglutide and DehydraTECH-cannabidiol compositions across 8-11 different study arms. Blood and brain tissue

Lexaria Announces New R&D Plans for 2026

Wed, 04 Mar 2026 09:25:00 -0500

Exciting new human and animal studies designed to enhance business opportunities

KELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the beginning of its 2026 research and development program (the "2026 R&D Program") designed to broaden pharmaceutical, intellectual property ("IP"), and business development opportunities through new and improved formulations.

Information on 3 new studies from the 2026 R&D Program which are representative of the Company's primary areas of focus during at least the first three quarters of

Lexaria Announces New R&D Plans for 2026

Wed, 04 Mar 2026 09:25:00 -0500

Exciting new human and animal studies designed to enhance business opportunities

Information on 3 new studies from the 2026 R&D Program which are representative of the Company's primary areas of focus during at least the first three quarters of

Form 8-K Lexaria Bioscience Corp. For: Feb 04

Fri, 06 Feb 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20260206/25962081.html

Form 8-K Lexaria Bioscience Corp. For: Feb 04

Fri, 06 Feb 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20260206/25962081.html

Lexaria Announces Positive Final Results From Human Pilot Study #5

Thu, 05 Feb 2026 09:15:00 -0500

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product

KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda^® branded liraglutide ("SAX-LIR").

"We are extremely pleased with the results of Human Pilot Study #5," stated Richard Christopher, CEO of Lexaria. "In addition to achieving the Study's primary safety and tolerability endpoint, we also

Lexaria Announces Positive Final Results From Human Pilot Study #5

Thu, 05 Feb 2026 09:15:00 -0500

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product

Form 8-K Lexaria Bioscience Corp. For: Jan 27

Wed, 28 Jan 2026 13:51:00 -0500

si-local-file:///var/storage/secattach/20260128/25907574.html

Form 8-K Lexaria Bioscience Corp. For: Jan 27

Wed, 28 Jan 2026 13:51:00 -0500

si-local-file:///var/storage/secattach/20260128/25907574.html

Form S-8 Lexaria Bioscience Corp.

Wed, 28 Jan 2026 13:34:00 -0500

si-local-file:///var/storage/secattach/20260128/25907443.html

Form S-8 Lexaria Bioscience Corp.

Wed, 28 Jan 2026 13:34:00 -0500

si-local-file:///var/storage/secattach/20260128/25907443.html

Lexaria receives six new patents, bringing total to 60 worldwide

Thu, 22 Jan 2026 09:22:38 -0500

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced it has been awarded six additional patents, bringing its total patent portfolio to 60 granted patents across major global markets.

The company received its first patent in Australia for patent Family #20, covering compositions and methods for sublingual delivery of nicotine, where it already holds patents in the United States, Canada, and Japan.

Lexaria obtained its first European Union patent in Family #21 for compositions and methods for treating hypertension, adding to three existing U.S. patents in this category. The company noted that Europe represents the second-largest hypertension market globally after the United States.

For patent Family

Lexaria Awarded Six Additional Patents

Thu, 22 Jan 2026 09:20:00 -0500

Lexaria now has 60 patents granted around much of the world
Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting

KELOWNA, BC / ACCESS Newswire / January 22, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has reached yet another important milestone in its strategy of building a strong and diverse intellectual property portfolio: the Company now has a total of 60 valid patents granted around most of the major potential markets around the world.

Lexaria's previous update on

Lexaria Awarded Six Additional Patents

Thu, 22 Jan 2026 09:20:00 -0500

Lexaria now has 60 patents granted around much of the world
Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting

Lexaria's previous update on

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Wed, 21 Jan 2026 09:55:00 -0500